Ajanta Pharma is currently trading at Rs. 1434.25, up by 37.05 points or 2.65% from its previous closing of Rs. 1397.20 on the BSE.
The scrip opened at Rs. 1421.00 and has touched a high and low of Rs. 1448.80 and Rs. 1420.00 respectively. So far 4,495 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720.00 on 12-Aug-2015 and a 52 week low of Rs. 1090.00 on 23-Mar-2015.
Last one week high and low of the scrip stood at Rs. 1448.80 and Rs. 1274.00 respectively. The current market cap of the company is Rs. 12,680.00 crore.
The promoters holding in the company stood at 73.78% while Institutions and Non-Institutions held 10.76% and 15.46% respectively.
Ajanta Pharma has received final approval of Almotriptan Malate Tablets (6.25 mg a 12.5 mg), a generic version of Axert for the treatment of acute migraine pain relief, from the US Food and Drug Administration (FDA). Ajanta Pharma USA Inc., a wholly owned subsidiary of the company, is scheduled to launch Almotriptan Tablets in US shortly.
Almotriptan Tablets is part of an ever-growing portfolio that the company has developed for the US market. To date, FDA has granted the company eight ANDA final approvals and two tentative approvals. An additional 16 ANDAs are under review with FDA.
Ajanta Pharma is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries.
